cyrilzakka/clinical-trials huggingface dataset:
Autoantibodies Prevalence During Checkpoint Inhibitor Treatment

The use of Checkpoint inhibitors (ICIs) is rapidly expanding to the treatment of many cancer types. Autoimmunity and clinical autoimmune diseases represent adverse events of ICIs with variable severity and consequences. Clinical trials using ICIs have largely excluded patients with preexisting autoimmune diseases but the rate of autoimmune flares has been reported to be high in patients with preexisting autoimmune diseases in retrospective cohort studies. Moreover numerous retrospective cases and series reported ICI-related autoimmune diseases in patients without any previous autoimmune event.

To date, no study has prospectively evaluated the rate of biological and clinical autoimmunity in patients. Moreover, guidelines concerning autoantibodies monitoring in patients are subject of debate.

The aim of this prospective study is to determine development or increase level frequencies of different types of autoantibodies in patients receiving ICI for the first time. The rate of clinical autoimmunes diseases development will also be recorded and correlated with autoantibodies prevalence before and during ICI treatment.

Results will help to determine the rate of biological and clinical autoimmune events induced by ICIs in unselected patients and will help to clarify autoimmunity screening strategy in this setting.

Eligibility Criteria:
Inclusion Criteria:

* patients receiving check point inhibitor for a neoplasic disease in a center that participates to the study during the inclusion period
* patients who agree to participate in the study
* adult patients (aged more than 18 years old)

Exclusion Criteria:

- previous treatment with check point inhibitor
Efficacy of Acupuncture and Moxibustion Treatment in Patients With Quiescent Crohn's Disease:Evaluation With fMRI

The purpose of this study is to determine whether acupuncture or moxibustion therapies are effective in the treatment of Crohn's disease. Meanwhile, the investigators aim to evaluate the efficacy by functional magnetic resonance imaging.

The purpose of this study is to determine whether acupuncture or moxibustion therapies are effective in the treatment of Crohn's disease. meanwhile, the investigators aim to evaluate the efficacy by functional magnetic resonance imaging.

Through treating quiescent Crohn's disease by electroacupuncture or moxibustion therapies for 12 weeks, Compare the different brain activation by the different therapies and observe the correlation between brain activation and efficacy.

Eligibility Criteria:
Inclusion Criteria:

* age 18-50 years;
* right-handed;
* clinical remission (Crohn's Disease Activity Index \[CDAI\]≤150) for at least 6 months prior to the study;
* C-reactive protein(CRP)\<10 mg/l;
* erythrocyte sedimentation rate (ESR) \<20 mm/h
* signing awritten informed consent form.

Exclusion Criteria:

* use of corticosteroids and psychotropic medications in the previous 30 days;
* current or prior history of neurological or psychiatric disease based
* on physicians' examination and questionnaires;
* current or prior history of neurosurgery, head injury, cerebrovascular
* insult, or brain trauma involving loss of consciousness;
* learning disability;
* claustrophobia;
* presence of metallic implants in the body;
* being pregnant or during lactation.
Mechanisms of Chiropractic Spinal Manipulation for Chronic Low Back Pain

This is a mechanistic randomized controlled trial on the effects of chiropractic spinal manipulative therapy on patients with chronic low back pain. It is designed as a mechanistic trial, in which the main objective is to identify which variables related to central sensitization can help predict the response to spinal manipulation, and the evolution of which of these variables can help explain clinical changes in chronic low back pain patients receiving spinal manipulative therapy.

The study is a mechanistic randomized controlled trials on the effects of chiropractic spinal manipulative therapy on patients with chronic low back pain. 100 chronic low back pain patients will be randomly allocated to receive 12 sessions over 4 weeks of spinal manipulative therapy or placebo spinal manipulation. The main objective is to identify variables related to a central sensitization or nociplastic pain phenotype can help predict the response to spinal manipulation. Additionally, changes in these variables during the treatment period will be used to identify potential pain mechanisms involved in pain relief by spinal manipulation. An additional group of 50 healthy volunteers will be used to measure the same variables and their evolution during 4 weeks in a healthy control population. Response to treatment will be measured according to changes in pain intensity and disability.

Eligibility Criteria:
Healthy volunteers will be accepted for that specific comparison group. Those volunteers must demonstrate no evidence of any systemic pathology, inflammatory, psychiatric, neurological or pain condition.

Inclusion Criteria:

* diagnosis of primary chronic low back pain (performed in the initial evaluation or previously received by a healthcare professional), with or without leg pain
* minimum of three months of duration

Exclusion Criteria:

* diagnosis of neuropathic pain in the lower extremity
* evidence of specific pathology affecting the lumbar spine
* diagnosis of psychiatric disorder or pain disorder affecting the hand/thumb or in the vicinity of the lumbar area
* intake corticosteroids, opioids or anticytokine medications
* pregnancy
* having been treated with spinal manipulation in the previous 12 months
Effect of Irrigation-Activation Techniques on Healing in Large Periapical Lesions

The aim of this study was to highlight the healing rates of large periapical lesions after different irrigation activation treatments as manual dynamic activation (MDA), passive ultrasonic irrigation (PUI), shock wave-enhanced emission photoacoustic streaming (SWEEPS) using CBCT scans based on volumetric change analysis during 1-year follow-up.

The aim of this study was to highlight the healing rates of large periapical lesions after different irrigation activation treatments as manual dynamic activation (MDA), passive ultrasonic irrigation (PUI), shock wave-enhanced emission photoacoustic streaming (SWEEPS) using CBCT scans based on volumetric change analysis during 1-year follow-up.

A total of 56 systemically healthy male/female patients with mandibular single-rooted teeth with a periapical index score (PAI) of 3 or higher were included in the study. Pretreatment lesion volumes were determined by CBCT. Patients were randomly divided into 3 study groups (PUI, SWEEPS, MDA) and control group (n=14). For the follow-up routine, 2D radiographs were taken at months 3, 6, and 9, as well as clinical examinations. At the end of 12 months, 3D evaluation of lesion volumes was performed using ITK SNAP. Pretreatment and follow-up values were statistically analyzed with the Wilcoxon test.

Eligibility Criteria:
Inclusion Criteria:

* Patients having single root mandibular teeth
* Patients the diagnosis of chronic apical periodontitis,
* Periapical index score of 3 and above,
* Patients having good oral hygiene

Exclusion Criteria:

* Patients with systemic diseases (diabetes, hypertension, chronic liver disease, coagulation disorders),
* Patients with bone metabolism disease and/or
* Patients using drugs that affect bone metabolism (such as steroids, bisphosphonates)
* Patients with a history of radiotherapy
* Pregnant patients
* Teeth with mobility of 2 or more, periodontal pocket depth of 5 mm or more, generalized chronic periodontitis, internal and external resorption, and/or vertical and horizontal root fractures
VIR-1111: A Prototype Human CMV-based Vaccine for Human Immunodeficiency Virus (HIV) in Healthy Volunteers

This is a Phase 1a, first in human study in which healthy adult participants who are considered to be at low-risk for HIV infection and are seropositive for cytomegalovirus (CMV) will receive two doses of VIR-1111 or placebo. These participants will be assessed for safety, reactogenicity, tolerability and immunogenicity. There is an optional long-term follow-up study that would lengthen study participation for up to 3 years post-first dose.


Eligibility Criteria:
Inclusion Criteria:

* Healthy males or healthy females of non-child-bearing potential between the ages of 18 to 50 at the time of screening
* Positive CMV serostatus
* Assessed by clinic staff as being low risk for HIV infection and committed to maintaining behavior consistent with low risk of HIV exposure through the last protocol visit
* Willing to use condoms during intercourse through Week 36 or the end of the study
* Willing to undergo HIV testing, risk reduction counseling, and receive HIV test results
* Willing to comply with the protocol requirements regarding donation of blood, sperm or other tissues
* In the opinion of the Investigator, generally in good health as determined from medical history and no clinically significant findings from physical examinations, vital signs, and laboratory values

Exclusion Criteria:

* Live in a home with children under the age of 6
* Routine provision of child care to children under the age of 6
* Have close contact with immunocompromised individuals
* Have close contact with pregnant women or a partner planning to become pregnant during the course of the study
* Health care provider who routinely comes into contact with immunosuppressed patients or pregnant women
* Participant is immunocompromised
* Participant has an autoimmune disorder
* Positive HIV test at the time of study screening
* Receipt of another investigational HIV or CMV vaccine candidate
Assessing Cognitive Decline at Home

Neuropsychiatric symptoms (NPS) refer to a range of mental and emotional issues that can be observed through how patients move, perform daily tasks, and express feelings on their faces. In this study, the investigators want to find ways to accurately and unobtrusively track these symptoms in people's homes over time. Our goals are to note when these symptoms happen, predict potential problems, and gather clear data to help doctors make accurate diagnoses.

To do this, the investigators will first collect information from participants who have in-home sensors. the investigators will then use special computer programs that can recognize everyday activities and identify features that connect to scores from the Mild Behavioral Impairment Checklist (MBI-C). These scores will be compared to a questionnaire (NPIQ) filled out by caregivers or family members, along with any relevant information from doctors about the patients' symptoms. The investigators aim to see how these features can help differentiate between types of NPS, such as mood changes and agitation.

Finally, the investigators will create a dashboard for doctors that summarizes the patterns of these symptoms in patients, making it easier to monitor and manage their mental health.

What the investigators would need from participants:

* Collect the participants' own data of daily activities from a room in participants home such as the participant's living room via a small camera the investigators provide for no less than 7 days and up to 30 days. The participant will have full control over the camera to turn on and off.
* The participant and a loved one will regularly answer short surveys asking about the participant's mood and daily functioning.
* At the end of agreed observation period, return the memory card of the participant's collected data from the camera in person or pre-paid FedEx envelope.

Eligibility Criteria:
Inclusion criteria:

* Age 65+ years old
* Any age and ethnicity.
* With or without, or at risk of mild to moderate dementia.
* Availability of a study partner (informant) who has contact with the patient at least once a week (this can also be the surrogate/LAR but does not necessarily have to be)

Exclusion criteria:

* Those with severe mobility impairments
* participants in non-home settings (skilled nursing facilities, etc.).
Normative Values for the German Version of the Montreal Cognitive Assessment (MoCA)

This observational cohort study in healthy volunteers establishes normative data for the German version of the Montreal Cognitive Assessment (MoCA) and investigates the possible impacts of demographics on the MoCA total score.

The Montreal Cognitive Assessment (MoCA) is a short tool to evaluate a multitude of cognitive domains (visuospatial / executive functioning, object naming, memory, attention, language, abstraction, orientation). The original English MoCA consistently showed very high sensitivity and specificity in distinguishing patients with mild cognitive impairment from healthy controls. Therefore it is an excellent tool for early recognition of cognitive disorders. Based on a Canadian sample, the MoCA proposes a cut-off-value of 26/30 points. However, there is increasing evidence of intercultural differences in terms of the best cut-off-score. In addition the original version only slightly corrects for possible influences of education - an adjustment for age- or gender-related effects is missing. Therefore, the aim of our study was to investigate the possible impacts of demographics on the MoCA total score and to provide normative values for a German-speaking population.

Eligibility Criteria:
Inclusion Criteria:

* Age ≥65 years
* Education ≥7 years
* Fluency in the German language
* Written informed consent

Exclusion Criteria:

* History of cognitive impairment
* Depression
* Severe sensory or motor impairment interfering with cognitive testing
* Serious somatic disease
* Disease or event affecting the central nervous system
* Cerebrovascular disease
* Regular medication with psychoactive drugs except for benzodiazepines
* Participation in a cognitive study within the last 3 months
Bougie Assisted Endotracheal Intubation in Air-Q Intubating Laryngeal Mask And Fastrach Intubating Laryngeal Mask

This study aims to compare using bougie as an assistant for endotracheal intubation through Air-Q and Fastrach intubating laryngeal mask devices when blind intubation fails as attempt to increase its success rate.

The investigators hypothesis that using bougie with its smaller caliber or lesser size can facilitate intubation and improve success rate when blind intubation through both devices fails.

Study objectives

* To make a comparison between Air-Q intubating laryngeal mask and Fastrach intubating laryngeal mask by using bougie assisted endotracheal intubation through both devices in patients undergoing elective surgeries in Suez Canal Hospitals.
* To assess the first trial success rate, the total success rate, time to tracheal intubation, the number of attempts, hemodynamics and adverse events.

Eligibility Criteria:
Inclusion Criteria:

* Patient aged \>18 years old.
* Gender both male and female.
* Patients are ASA I (American Society of Anesthesiologists' physical status Grade I) normal healthy patients or ASA II patients with mild systemic disease and no functional limitations

Exclusion Criteria:

* Any disorder of the cardiovascular, pulmonary, hepatic, renal, or gastrointestinal systems known from history or general examination.
* Patients with unstable cervical spine
* Any medical disease that may affect airway as Rheumatoid arthritis.
* Patient refusal to participate in the study.
Depression Study In Elderly Patients

Major Depressive Disorder (MDD) Study in Elderly Outpatients


Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of Major Depressive Disorder (MDD).
* Current major depressive episode at screen at least 2 months duration.
* Must be at least 60 years of age.

Exclusion Criteria:

* Patients with a primary diagnosis other than MDD.
* Patients with a history of schizophrenia, schizoaffective disorder, bipolar disorder or dementia.
* Patients with a history of brief depressive episodes lasting less than 8 weeks.
* Patients receiving formal psychotherapy within 12 weeks of study.
* Patients who are suicidal.
* Patients who have received electroconvulsive therapy or transcranial magnetic stimulation within 6 months prior to screening.
* Patients with a history or seizure disorders.
EndogenousTestosterone Response to a Testosterone Boosting Supplement

The purpose of this study is to determine whether a proprietary 'testosterone-boosting' supplement, when used as recommended by the manufacturer, results in an increase in testosterone levels as measured by a salivary free testosterone assay.

The experimental intervention in this study is the daily administration of a testosterone boosting supplement or sham supplement for 4 weeks. The supplement will be administered daily in capsule form. The control group will be given a sham capsule containing the carrier components of the supplement. Participants will be asked not to modify their current lifestyle. Salivary testosterone levels will be assessed prior to the intervention to collect a baseline measurement for each subject, and following the intervention to evaluate any changes in hormone levels.

Eligibility Criteria:
Inclusion Criteria:

* Adult male aged 20 to 40 years.
* Fluent in English.

Exclusion Criteria:

* Currently receiving hormonal therapy or testosterone boosting supplement.
* Has received hormonal therapy or testosterone boosting supplement within 3 months prior to study.
* Has experienced adverse event following previous exposure to testosterone boosting supplements.
EFFECT OF CRYOLIPOLYSIS ON HORMONAL PROFILE AND MENSTRUAL REGULARITYIN OBESE WITH PCOS

The effecting study to determine the impact of cryolipolysis on obese women with pcos

Polycystic ovary syndrome(PCOS) is the most common endocrine disorder in women of reproductive age. Women with this syndrome may have infrequent menstrual periods or amenorrhea and excess androgen levels. The ovaries develop numerous small follicles and fail to ovulate on a regular basis, with subsequent subfertility in those women that wish to conceive.The etiology of PCOS is unclear. Early diagnosis and treatment may reduce the risk of long-term complications such as type 2 diabetes and heart disease ,PCOS affects 5-20% of women of reproductive age worldwide. The condition is characterized by hyperandrogenism, ovulatory dysfunction and polycystic ovarian morphology (PCOM) with excessive androgen production by the ovaries being a key feature of PCOS. PCOS is classified into four separate phenotypes (A-D), according to the presence or absence of three characteristics: hyperandrogenism (either biochemical or clinical), ovulatory dysfunction and polycystic ovarian morphology. Only phenotype A requires all three features of PCOS to be present. The various diagnostic criteria currently available for PCOS include a greater or fewer number of PCOS phenotypes. AE-PCOS, Androgen Excess-PCOS Society; NIH, National Institutes of Health ,the trial made on 2group ,control group and study group for 3 months

Eligibility Criteria:
Inclusion Criteria:

All patient age from 18to 30 Waist hip ratio \>.9

Exclusion Criteria:

* thyroid disorders. Hepatic diseases. Skin or bleeding disorders. Chronic disease or illnessCardiovascular and pulmonary disease,Cancer diseases., Renal failure disease. Recent surgery. hose with pacemakers or surgical implants. Musculoskeletal problems that would limit WBV.Raynaud's phenomenon. A rare condition in which cold temperatures can impede blood flow to the fingers and toes. Other conditions that pose a risk include,Pregnancy or breast-feeding,Inflammatory skin disorders,Skin conditions caused by immune system disorders, such as eczema or psoriasis
Exploring Physical and Psychological Needs and Quality of Life in Patients With Advanced Cancer Receiving Immunotherapy

During the immune checkpoint inhibitor therapy (ICIT), most of the patients stay at home, but there is lacking of the studies to explore their physical and psychological distress, financial toxicity, care needs, and quality of life. Therefore, the aims of this program are to (1) explore the immune-related adverse event (irAE) severity, distress, financial toxicity, and quality of life and examine the psychometric testing of the Functional Assessment of Cancer Therapy-Immune Checkpoint Modulator (FACT-ICM); (2) establish the LINE group for assessing irAE severity and change trajectory of quality of life in one-year follow-up and (3) combined retrospective chart review and the finding in aim (2) to develop the risk prediction model in order to identify the high risk population.

To achieve aim 1, a cross-sectional design is conducted to explore irAE severity, distress, financial distress, and quality of life in mixed type of cancer patients receiving ICIT. A structural questionnaire will be used including Common Terminology Criteria for adverse events (CTCAE) 33 items, Distress Thermometer (DT), the Comprehensive Score for financial Toxicity (COST), FACT-ICM, and EORTC-QLQ C30. Correlation analysis and exploratory factor analysis will be used to examine the psychometric testing of FACT-ICM.

To achieve aim 2 and 3, a prospective cohort study will be conducted to recruit 200 patients in first course receiving ICIT and follow for 1 year using LINE to report symptoms in weekly reporting within 3 months and once in 3-4 weeks in 4th -12th months during treatment. Data will be collected at five times (Before treatment for baseline, the 3th, 6th 9th 12th months) using a set of questionnaires including CTCAE 33 items, DT, COST, Supportive Care Needs Scale-short form34, and FACT-ICM.

Eligibility Criteria:
Inclusion Criteria:

* (1) Patients diagnose cancer and are informed
* (2) Aged ≥18 years old
* (3) Conscious clear and able to communicate

Exclusion Criteria:

* (1) Patients who are under other clinical trial
Remimazolam Versus Midaszolam for Sedation in Diagnostic Upper Gastrointestinal Endoscopy

The goal of this clinical trial is to compare the efficacy of remimazolam with midazolam in patients undergoing gastrointestinal endoscopy. The main questions it aims to answer are:

* Superiority of total procedure time in remimazolam compared to midazolam
* The success of sedation time

This is the single blind study.; Patients will not know what they are given as the sedation drug If there is a comparison group: Researchers will compare patients with midazolam group to see if remimazolam group is superior to midazolam group


Eligibility Criteria:
Inclusion Criteria:

* Patients who agreed for this clinical trials
* Patients who want diagnostic endoscopy under sedation
* The total procedure time which is predicted within 15 minutes
* ASA \>=2
* BMI more than 18.5kg/m2, less than 30kg/m2

Exclusion Criteria:

* Patients who have stomach illness
* Patients with respiratory disease
* Mallampati Score\>=3
* Systolic BP \>160mmHg or \<90mmHg
* Refractory Hypertension
* Uncontrolled glaucoma
* Severe liver failure or chronic kidney disease
* Patients with drug abuse or alcohol abuse within 1 year
* Patients who are sensitive for certain medication (such as benzodiazepine, remimazolam)
* Obstructive sleep dyspnea patients
* Galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption
* Pregnant, breast feeding patient